

applied through the digestive tract, although improvement can be required to prolong its half life in the blood. In summary, DIF-1 may have potential as a novel oral anti-cancer agent with unique mechanisms of action and less toxicity.

In addition, *in-vitro* and *in-vivo* experiments using endothelial cells have shown that DIF-1 inhibits angiogenesis by reducing the expression of vascular endothelial growth factor receptor-2, which is independent of its effect on the Wnt/ β -catenin signaling pathway [26]. Therefore, inhibition of the Wnt/ β -catenin signaling pathway may not be the only mechanism for the anti-tumor effect of DIF-1. Despite our efforts and those of other research groups, the target molecule(s) of DIFs for its antiproliferative effect on mammalian cells has not yet been identified [40,41]. Identification of the target molecule(s) may not only reveal the precise mechanisms for the antiproliferative effect of DIFs but also offer novel anti-cancer drugs that suppress both tumor cell proliferation and neovascularization.

Acknowledgments

We thank Issei Egashira, Naoya Kubokura, Masaki Arioka and Fumie Shiraishi (Department of Clinical Pharmacology, Faculty of Medical Sciences, Kyushu University) for technical assistance and Minako Hirahashi (Department of Anatomic Pathology, Faculty of Medical Sciences, Kyushu University) for useful discussion. This study was supported by KAKENHI to FTY (21590284 and 25460334).

References

- [1] Nelson WJ, Nusse R. Convergence of Wnt, β -catenin, and cadherin pathways. *Science* 2004;303:1483–7.
- [2] Moon RT, Bowerman B, Boutros M, Perrimon N. The promise and perils of Wnt signaling through β -catenin. *Science* 2002;296:1644–6.
- [3] Akiyama T. Wnt/ β -catenin signaling. *Cytokine Growth Factor Rev* 2000;11:273–82.
- [4] Sherr CJ. Cancer cell cycles. *Science* 1996;274:1672–7.
- [5] Meyer N, Penn LZ. Reflecting on 25 years with MYC. *Nat Rev Cancer* 2008;8:976–90.
- [6] Barnes DM, Gillett CE. Cyclin D1 in breast cancer. *Breast Cancer Res Treat* 1998;52:1–15.
- [7] Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. *Oncogene* 1999;18:3004–16.
- [8] Utsunomiya T, Doki Y, Takemoto H, Shiozaki H, Yano M, Sekimoto M, et al. Correlation of β -catenin and cyclin D1 expression in colon cancers. *Oncology* 2001;61:226–33.
- [9] Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview Cyclin D1: normal and abnormal functions. *Endocrinology* 2004;145:5439–47.
- [10] Logan CY, Nusse R. The Wnt signaling pathway in development and disease. *Annu Rev Cell Dev Biol* 2004;20:781–810.
- [11] Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of β -catenin-Tcf signaling in colon cancer by mutations in β -catenin or APC. *Science* 1997;275:1787–90.
- [12] Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. *Nat Genet* 2000;24:245–50.
- [13] McDonald SA, Preston SL, Lovell MJ, Wright NA, Jankowski JA. Mechanisms of disease: from stem cells to colorectal cancer. *Nat Clin Pract Gastroenterol Hepatol* 2006;3:267–74.
- [14] Segditsas S, Tomlinson I. Colorectal cancer and genetic alterations in the Wnt pathway. *Oncogene* 2006;25:7531–7.
- [15] Cohen P, Frame S. The renaissance of GSK3. *Nat Rev Mol Cell Biol* 2001;2:769–76.
- [16] Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. *Biochem J* 2001;359:1–16.
- [17] Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3 β regulates cyclin D1 proteolysis and subcellular localization. *Genes Dev* 1998;12:3499–511.
- [18] Takahashi-Yanaga F, Sasaguri T. GSK-3 β regulates cyclin D1 expression: a new target for chemotherapy. *Cell Signal* 2008;20:581–9.
- [19] Morris HR, Taylor GW, Masento MS, Jermyn KA, Kay RR. Chemical structure of the morphogen differentiation inducing factor from *Dictyostelium discoideum*. *Nature* 1987;328:811–4.
- [20] Morris HR, Masento MS, Taylor GW, Jermyn KA, Kay RR. Structure elucidation of two differentiation inducing factors (DIF-2 and DIF-3) from the cellular slime mould *Dictyostelium discoideum*. *Biochem J* 1988;249:903–6.
- [21] Takahashi-Yanaga F, Taba Y, Miwa Y, Kubohara Y, Watanabe Y, Hirata M, et al. Dictyostelium differentiation-inducing factor-3 activates glycogen synthase kinase-3 β and degrades cyclin D1 in mammalian cells. *J Biol Chem* 2003;278:9663–70.
- [22] Yasmin T, Takahashi-Yanaga F, Mori J, Miwa Y, Hirata M, Watanabe Y, et al. Differentiation-inducing factor-1 suppresses gene expression of cyclin D1 in tumor cells. *Biochem Biophys Res Commun* 2005;338:903–9.
- [23] Mori J, Takahashi-Yanaga F, Miwa Y, Watanabe Y, Hirata M, Morimoto S, et al. Differentiation-inducing factor-1 induces cyclin D1 degradation through the phosphorylation of Thr²⁸⁶ in squamous cell carcinoma. *Exp Cell Res* 2005;310:426–33.
- [24] Takahashi-Yanaga F, Mori J, Matsuzaki E, Watanabe Y, Hirata M, Miwa Y, et al. Involvement of GSK-3 β and DYRK1B in differentiation-inducing factor-3-induced phosphorylation of cyclin D1 in HeLa cells. *J Biol Chem* 2006;281:38489–97.
- [25] Matsuzaki E, Takahashi-Yanaga F, Miwa Y, Hirata M, Watanabe Y, Sato N, et al. Differentiation-inducing factor-1 alters canonical Wnt signaling and suppresses alkaline phosphatase expression in osteoblast-like cell lines. *J Bone Miner Res* 2006;21:1307–16.
- [26] Yoshihara T, Takahashi-Yanaga F, Shiraishi F, Morimoto S, Watanabe Y, Hirata M, et al. Anti-angiogenic effects of differentiation-inducing factor-1 involving VEGFR-2 expression inhibition independent of the Wnt/ β -catenin signaling pathway. *Mol Cancer* 2010;9:245.
- [27] Jingushi K, Takahashi-Yanaga F, Yoshihara T, Shiraishi F, Watanabe Y, Hirata M, et al. DIF-1 inhibits the Wnt/ β -catenin signaling pathway by inhibiting TCF7L2 expression in colon cancer cell lines. *Biochem Pharmacol* 2012;83:47–56.
- [28] Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, Williams GT, et al. Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors. *Nat Genet* 2002;30:227–32.
- [29] Sampson JR, Dolwani S, Jones S, Eccles D, Ellis A, Evans DG, et al. Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. *Lancet* 2003;362:39–41.
- [30] Sieber OM, Lipton L, Crabtree M, Heinemann K, Fidalgo P, Phillips RK, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. *N Engl J Med* 2003;348:791–9.
- [31] Sakamoto K, Tominaga Y, Yamauchi K, Nakatsu Y, Sakumi K, Yoshiyama K, et al. MUTYH-null mice are susceptible to spontaneous and oxidative stress induced intestinal tumorigenesis. *Cancer Res* 2007;67:6599–604.
- [32] Masento MS, Morris HR, Taylor GW, Johnson SJ, Skapski AC, Kay RR. Differentiation-inducing factor from the slime mould *Dictyostelium discoideum* and its analogues. Synthesis, structure and biological activity. *Biochem J* 1988;256:23–8.
- [33] Traynor D, Kay RR. The DIF-1 signaling system in *Dictyostelium*. Metabolism of the signal. *J Biol Chem* 1991;266:5291–7.
- [34] Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. *N Engl J Med* 2000;342:1946–52.
- [35] Ohtsubo T, Nishioka K, Imaiso Y, Iwai S, Shimokawa H, Oda H, et al. Identification of human MutY homolog (hMYH) as a repair enzyme for 2-hydroxyadenine in DNA and detection of multiple forms of hMYH located in nuclei and mitochondria. *Nucleic Acids Res* 2000;28:1355–64.
- [36] Hirano S, Tominaga Y, Ichinoe A, Ushijima Y, Tsuchimoto D, Honda-Ohnishi Y, et al. Mutator phenotype of MUTYH-null mouse embryonic stem cells. *J Biol Chem* 2003;278:38121–24.
- [37] Klungland A, Rosewell I, Hollenbach S, Larsen E, Daly G, Epe B, et al. Accumulation of premutagenic DNA lesions in mice defective in removal of oxidative base damage. *Proc Natl Acad Sci USA* 1999;96:13300–05.
- [38] Sakoguchi-Okada N, Takahashi-Yanaga F, Fukada K, Shiraishi F, Taba Y, Miwa Y, et al. Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. *Biochem Pharmacol* 2007;73:1318–29.
- [39] Takahashi-Yanaga F, Yoshihara T, Jingushi K, Miwa Y, Morimoto S, Hirata M, et al. Celecoxib-induced degradation of T-cell factors-1 and -4 in human colon cancer cells. *Biochem Biophys Res Commun* 2008;377:1185–90.
- [40] Matsuda T, Takahashi-Yanaga F, Yoshihara T, Maenaka K, Watanabe Y, Miwa Y, et al. Dictyostelium differentiation-inducing factor-1 binds to mitochondrial malate dehydrogenase and inhibits its activity. *J Pharmacol Sci* 2010;112:320–6.
- [41] Shimizu K, Murata T, Tagawa T, Takahashi K, Ishikawa R, Abe Y, et al. Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1) is a pharmacological target of differentiation-inducing factor-1, an antitumor agent isolated from *Dictyostelium*. *Cancer Res* 2004;64:2568–71.

Mismatch Repair Deficient Mice Show Susceptibility to Oxidative Stress-Induced Intestinal Carcinogenesis

Jingshu Piao¹, Yoshimichi Nakatsu¹, Mizuki Ohno¹, Ken-ichi Taguchi², Teruhisa Tsuzuki¹ ✉

1. Department of Medical Biophysics and Radiation Biology, Graduate School of Medical Sciences, Kyushu University,
2. Department of Cancer Pathology, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka, Japan

✉ Corresponding author: Teruhisa Tsuzuki, Department of Medical Biophysics and Radiation Biology, Faculty of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan. Phone: +81-92-642-6141; fax: +81-92-642-6145; E-mail: tsuzuki@med.kyushu-u.ac.jp

© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (<http://creativecommons.org/licenses/by-nc-nd/3.0/>). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.

Received: 2012.12.21; Accepted: 2013.07.24; Published: 2013.12.19

Abstract

We have previously established an experimental system for oxidative DNA damage-induced tumorigenesis in the small intestine of mice. To elucidate the roles of mismatch repair genes in the tumor suppression, we performed oxidative DNA damage-induced tumorigenesis experiments using *Msh2*-deficient mice. Oral administration of 0.2% Potassium Bromate, $KBrO_3$, effectively induced epithelial tumors in the small intestines of *Msh2*-deficient mice. We observed a 22.5-fold increase in tumor formation in the small intestines of *Msh2*-deficient mice compared with the wild type mice. These results indicate that mismatch repair is involved in the suppression of oxidative stress-induced intestinal tumorigenesis in mice. A mutation analysis of the *Cttnb1* gene of the tumors revealed predominant occurrences of G:C to A:T transitions. The TUNEL analysis showed a decreased number of TUNEL-positive cells in the crypts of small intestines from the *Msh2*-deficient mice compared with the wild type mice after treatment of $KBrO_3$. These results suggest that the mismatch repair system may simultaneously function in both avoiding mutagenesis and inducing cell death to suppress the tumorigenesis induced by oxidative stress in the small intestine of mice.

Key words: HNPCC, oxidative DNA damage, Wnt signaling pathway, mutagenesis, cell death

Introduction

Reactive oxygen species (ROS) are generated by the normal cellular metabolism and also by exposure to environmental factors, such as radiation and chemicals. ROS constantly induce various lesions in the DNA of living organisms under physiological conditions, and the resulting DNA damage causes mutations and cell death, leading to aging-associated diseases, such as cancer and neurodegeneration (1). Among the various types of oxidative DNA damage, oxidized guanine, 8-oxo-7, 8-dihydroguanine (8-oxoG) is abundant and highly mutagenic because of its ambiguous base-pairing properties; it can be paired with adenine as well as with cytosine (2-6). Therefore, 8-oxoG in DNA causes G:C to T:A transversions after two rounds of DNA replication. In

mammalian cells, the base excision repair (BER) pathway initiated by OGG1 or MUTYH plays a role in the suppression of 8-oxoG-related mutagenesis. OGG1, an 8-oxoG DNA glycosylase, excises the 8-oxoG paired with cytosine from DNA (7, 8). MUTYH is an adenine DNA glycosylase that excises the adenine incorporated opposite 8-oxoG from DNA (9-12). The synergistic actions of OGG1 and MUTYH suppress the mutagenesis caused by 8-oxoG in DNA.

In addition to DNA repair, a nucleotide pool sanitizing enzyme, MTH1, suppresses the mutagenesis induced by oxidative stress (13, 14). This enzyme can hydrolyze oxidized purine nucleotides, such as 8-oxo-dGTP, 2-OH-dATP and 8-OH-dATP, to prevent the incorporation of mutagenic nucleotides into DNA

during replication (15, 16). In addition to 8-oxoG, a wide variety of oxidatively modified bases in DNA were removed by the BER pathway following initiation by various DNA glycosylases (17).

Besides BER, mismatch repair (MMR) is also involved in the repair of oxidative DNA damage. MMR is an evolutionarily conserved system that corrects replication errors such as mismatched bases and small insertions/deletions. The MSH2/MSH6 heterodimer (MutS α) and MSH2/MSH3 heterodimer (MutS β) recognize mismatched bases and small insertions/deletions, respectively, and then recruit MutL α (MLH1 and PMS2 heterodimer) to initiate the MMR reaction (18). In addition to its role in correcting replication errors, MMR is known to involve in the induction of apoptosis in response to DNA lesions caused by alkylating agents (19-21). The human MMR genes are associated with hereditary non-polyposis colorectal cancer (HNPCC), which is a common cancer predisposition syndrome characterized by a dominant mode of transmission and high penetrance (22-25). deWeese *et al* reported that *Msh2*-deficient mouse embryonic stem (ES) cells showed the accumulation of oxidative DNA damage, such as 8-oxoG and thymine glycol, in their genomes, as well as tolerance to apoptosis caused by low dose gamma-ray irradiation (26). Based on the analysis of spontaneous mutational specificity of mice defective in the *Mth1* and/or the *Msh2* genes, we speculated that MMR might act to correct mispairs with the oxidized nucleotides (27). Furthermore, Colussi *et al*, and Russo *et al* reported that MMR could suppress the mutations caused by the incorporation of oxidized purine deoxynucleoside triphosphate (28, 29). These findings suggest the involvement of MMR in the suppression of oxidative stress-induced mutagenesis and tumorigenesis in mammals.

KBrO₃ is an oxidizing agent that is known to induce 8-oxoG in the DNA of rats and mice, and is recognized as a renal carcinogen in rats (30-33). We previously established an experimental system for oxidative DNA damage-induced tumorigenesis in the intestinal tract of mice using this agent (34). The oral administration of KBrO₃ for 16 weeks effectively induced epithelial tumors in the small intestines of *MutYh*-deficient mice, indicating the significance of MutYh in the suppression of tumorigenesis induced by oxidative stress (34).

In this study, we performed KBrO₃-induced tumorigenesis experiments using *Msh2*-deficient mice to elucidate the roles of MMR in the suppression of oxidative stress-induced tumorigenesis. We found that MMR plays a significant role in the suppression of oxidative stress-induced intestinal tumorigenesis in mice.

Materials and Methods

Animals

The *Msh2*-deficient mice used in this study were generated as reported previously (27). The wild type, heterozygous and homozygous mutant mice used in this study were obtained by intercrossing the heterozygous mutant mice. All animals were maintained under specific pathogen free (SPF) conditions. All animal care and handling procedures were approved by the Institutional Animal Care and Use Committee of Kyushu University, and followed the Guideline for Proper Conduct of Animal Experiments, Science Council of Japan.

KBrO₃ treatment

KBrO₃ (Sigma-ALDRICH) was given to 6-8-week-old mice in their drinking water at a concentration of 0.2% for 16 weeks. The body weight and consumption of drinking water were measured every week. After 16 weeks, all the animals were sacrificed, and the intestines were fixed with 10% phosphate buffered-formalin, and then stored in 70% ethanol.

Histological analysis

The inspections for tumor formation in the intestinal mucosa were carefully performed under a dissecting microscope. The small intestinal tumors were carefully removed from intestines, embedded in paraffin and sectioned. The sections were stained with hematoxylin and eosin for the diagnosis of the tumors. The evaluation of the tumors was performed according to the Vienna classification (35).

Mutation analysis of the *Ctnnb1* gene

The small intestinal tumors were carefully removed from the mucosa under a dissecting microscope. Genomic DNA was extracted using a DNeasy Tissue Kit (QIAGEN) according to the manufacturer's protocol. Eighty-nine small intestinal tumors obtained from five *Msh2*-deficient mice were analyzed for mutations in the *Ctnnb1* (β -catenin) gene. Thirty to fifty nanograms of genomic DNA extracted from each small intestinal tumor was used as the template for PCR with rTaq DNA polymerase (TaKaRa). The entire coding sequence of the second exon of the *Ctnnb1* gene was amplified using primers 5'-TCCTTGGCTGCCTTTCTAACAGTA-3' (upper) and 5'-GCATGCCCTCATCTAGCGTCT-3' (lower). Amplified DNA containing exon 2 of the *Ctnnb1* gene was purified with a PCR purification kit (QIAGEN) according to the manufacturer's protocol. The purified DNA fragments were used as a template for direct sequencing with a BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) and the se-

quences were determined with an ABI PRISM® 3100 Genetic Analyzer (Applied Biosystems).

TUNEL analysis

The intestines were removed from the wild type and mutant mice treated with KBrO_3 for 16 weeks, and 3 μm sections were made after the samples were embedded in paraffin. We analyzed the cell death (apoptosis) in the crypts of the small intestine using a TUNEL kit (TaKaRa) as described in the manual supplied by the manufacturer. We counted the TUNEL-positive cells in more than 100 crypts from five mice of each genotype.

Results

Tumor formation induced by KBrO_3 treatment in *Msh2*-deficient mice

In order to examine whether oxidative stress increases the intestinal tumorigenesis in mismatch repair-deficient mice, congenic wild type, heterozygous and homozygous *Msh2*-deficient (5, 6 and 7 animals for each genotype, respectively) mice were administered 0.2% KBrO_3 in their drinking water for 16 weeks. At the same time, five mice of each genotype were kept under the same conditions except for the KBrO_3 -treatment. As previously observed, the KBrO_3 -treatment appeared to cause a slowdown in the increase of body weight at almost the same rate in all groups of animals during the period of KBrO_3 -treatment. We dissected the mice after the 16-week treatment with KBrO_3 , and inspected the intestines under a dissecting microscope. In the homozygous *Msh2*-deficient mice treated with KBrO_3 , the formation of small intestinal tumors was dramatically increased (Figure 1, Table 1). The mean number of tumors induced in the small intestines of the seven *Msh2*-deficient mice was 27.0, whereas it was 1.2 and 1.5 in the five wild type and six heterozygous mice, respectively. Tumor formation was also observed in the untreated homozygous *Msh2*-deficient mice, albeit at a much lower frequency (mean: 1.2 tumor/mouse, $n=5$) compared with the treated homozygous mice. As previously observed in the *MutYh*-deficient mice (34), the KBrO_3 -induced tumors predominantly developed in the duodenum and in the upper region of the jejunum (Figure 1A). We found no other anomalies in the KBrO_3 -treatment mice.

Table 1. Tumor formation in the intestine of *Msh2*-deficient mice

Genotype	No treatment	KBrO_3 -treatment	
	No. of tumors ^a	No. of tumors ^a	Ratio ^b
Wild type	0	1.20 ± 0.98	1.00
Heterozygote	0	1.50 ± 1.26	1.25
Homozygote	1.20 ± 0.75	27.00 ± 7.44	22.50

a: The no. of tumors is the mean number of tumors per mouse, with the standard deviation. b: ratio to tumors in wild type mice




Figure 1. KBrO_3 -induced tumors in the small intestine of *Msh2*-deficient mice. **A.** The proximal regions of the small intestines of KBrO_3 -treated mice are shown; (+/+): wild type, (+/-): heterozygous *Msh2*-deficient, and (-/-): homozygous *Msh2*-deficient mice. Multiple polyp formations could be observed in the KBrO_3 -treated homozygous *Msh2*-deficient mice. **B.** A section of a KBrO_3 -induced tumor stained with hematoxylin and eosin (original magnification: objective 10X). The regions containing the neoplasia are encircled by a broken line.

Pathological analysis of tumors induced by KBrO_3 in the small intestines

We performed a pathological analysis of 25, three and two small intestinal tumors derived from five homozygous-deficient, three heterozygous *Msh2*-deficient mice and two wild type mice, respectively, according to the Vienna classification of gastrointestinal epithelial neoplasia (Table 2, Figure 1B). All tumors from homozygous *Msh2*-deficient mice were classified as category 4 (non-invasive high grade neoplasia), except for one case that was classified as category 3 (non-invasive low grade neoplasia). All tumors from wild type and heterozygous *Msh2*-deficient mice were also classified as category 4 (Table 2).

Table 2. Classification of KBrO_3 -induced small intestinal tumors in mice

Genotype	Category 3*	Category 4*			Total
		4.1	4.2	4.3	
Wild type	—	—	2	—	2
Heterozygote	—	—	3	—	3
Homozygote	1	3	21	—	25

*Tumors were categorized according to the Vienna classification of gastrointestinal epithelial neoplasia

Mutation analysis of the *Ctnnb1* gene

The β -catenin protein encoded by *Ctnnb1* gene is a transcriptional activator functioning in the Wnt-signaling pathway (36). The phosphorylation of β -catenin by GSK3 β in a complex with Axin and Apc is required for the ubiquitin-mediated degradation of β -catenin. Therefore, the presence of mutations affecting the phosphorylation of the protein lead to its stabilization and the accumulation of β -catenin in nuclei, inducing the expression of target genes such as c-myc and cyclin D1 without Wnt signaling. The mutations at four putative GSK3 β -phosphorylation sites (S33, S37, T41, S45) and amino acids adjacent these sites have been detected in a wide variety of human cancers including HNPCC, as well as in chemically-induced tumors in model animals. Therefore, we analyzed the mutations in exon 2 of the *Ctnnb1* gene encoding the GSK3 β -phosphorylation sites of β -catenin. Among 89 tumors from five homozygous *Msh2*-deficient mice, 27 tumors (30.3%) showed a mutation in this region (Figure 2, Table 3). All the mutations were base substitutions and occurred at or in the vicinity of the codons for S33, S37 and T41. No mutations were observed at the codon for S45. Among them, G:C to A:T transitions predominantly occurred; 20 mutations (74.1%) were identified as G:C to A:T transitions, and the others were three A:T to G:C transitions (11.1%), two G:C to T:A transversions and

two G:C to C:G transversions (7.4%, respectively). There is no clear hotspot for G:C to A:T transitions in this region, with there being seven at D32, five at S37, four at G34 and four at T41. However, besides one G:C to T:A transversion at S33, three other types of mutations were observed only at the codon for S37. The base substitutions observed at the codon for S37 were as follows; five G:C to A:T transitions, three A:T to G:C transitions, two G:C to C:G transversions and one G:C to T:A transversion.




Figure 2. Somatic mutations found in the *Ctnnb1* gene of tumors. The amino acid sequence and the corresponding nucleotide sequence of GSK3 β phosphorylation sites are shown at the top. The amino acids at phosphorylation sites are depicted in bold. The somatic mutations found in the KBrO₃-induced intestinal tumors are shown below the nucleotide sequence of the *Ctnnb1* gene; upper and lower panels show the nucleotide sequencing results from normal tissues and tumors, respectively.

Table 3. Mutations found in the *Ctnnb1* gene

Mouse ID	Sample ID	Nucleotide position	Wild type	Mutant	Mutation	Amino acid change
22	1	94	GAT	AAT	G:C→A:T	D32N
38	1	109	TCT	CCT	A:T→G:C	S37P
	4	109	TCT	CCT	A:T→G:C	S37P
	5	122	ACC	ATC	G:C→A:T	T41I
	7	101	GGA	GAA	G:C→A:T	G34E
	8	110	TCT	TAT	G:C→T:A	S37Y
	12	94	GAT	AAT	G:C→A:T	D32N
	13	100	GGA	AGA	G:C→A:T	G34R
	18	110	TCT	TTT	G:C→A:T	S37F
	20	110	TCT	TTT	G:C→A:T	S37F
	21	122	ACC	ATC	G:C→A:T	T41I
	22	94	GAT	AAT	G:C→A:T	D32N
48	4	110	TCT	TGT	G:C→C:G	S37C
	6	110	TCT	TTT	G:C→A:T	S37F
	10	94	GAT	AAT	G:C→A:T	D32N
	15	100	GGA	AGA	G:C→A:T	G34R
	22	109	TCT	CCT	A:T→G:C	S37P
45	1	122	ACC	ATC	G:C→A:T	T41I
	3	110	TCT	TGT	G:C→C:G	S37C
	9	110	TCT	TTT	G:C→A:T	S37F
	10	94	GAT	AAT	G:C→A:T	D32N
50	5	122	ACC	ATC	G:C→A:T	T41I
	8	100	GGA	AGA	G:C→A:T	G34R
	12	94	GAT	AAT	G:C→A:T	D32N
	14	94	GAT	AAT	G:C→A:T	D32N
	16	110	TCT	TTT	G:C→A:T	S37F
	24	98	TCT	TAT	G:C→T:A	S33Y




Figure 3. TUNEL-positive crypt cells in the small intestines from KBrO₃-treated mice. A. The sections stained with TUNEL. The crypts of small intestines from wild type (left) and *Msh2*-deficient (right) mice treated with KBrO₃. B. The number of TUNEL-positive cells in the crypts. The mean numbers of TUNEL-positive cells with standard deviations are indicated by white (wild type mice) and black (homozygous *Msh2*-deficient mice) bars. * $p < 0.002$ (Student's *t*-test).

Analysis of cell death

MMR is involved in the signaling for cell death induced by genotoxic chemicals, such as alkylating agents (19-21). A previous study showed that ES cells carrying disrupted *Msh2* alleles displayed an increased survival following exposure to low-level ionizing radiation compared with wild type ES cells (26). The increased survival could be attributed to a failure of the cells to efficiently execute apoptosis in response to oxidative DNA damage induced by radiation exposure. These findings suggested that MMR is involved in the induction of apoptosis caused by oxidative DNA damage. It has been shown that intestinal cancer originates in the stem cells resided in the bottom of intestinal crypts (37). Thus, in the present study, we analyzed the cell death in the crypts of small intestines from wild type and *Msh2*-deficient

mice treated with KBrO₃ using a TUNEL method. A few TUNEL-positive cells were detected in the crypts of wild type mice, but not in those of *Msh2*-deficient mice (Figure 3A). We counted the TUNEL-positive cells in more than 100 crypts from each genotype of mice. The average numbers of crypts per mouse were as follows: wild type, 21.2 (min 14, max 31) and *Msh2*-deficient, 21.6 (min 17, max 30). We found that 3.36 ± 0.96 (mean \pm SD) TUNEL-positive cells per crypt were present in wild type mice, while 0.80 ± 0.46 (mean \pm SD) TUNEL-positive cell per crypt were present in *Msh2*-deficient mice (Figure 3B). This difference was statistically significant ($p < 0.002$; *t*-test).

Discussion

In the present study, we performed KBrO₃-induced tumorigenesis experiments using *Msh2*-deficient mice to examine the involvement of mismatch repair (MMR) in the suppression of oxidative stress-induced tumorigenesis. The oral administration of KBrO₃ at a dose of 0.2% in drinking water dramatically increased the formation of intestinal tumors in *Msh2*-deficient mice compared to untreated *Msh2*-deficient mice and treated wild type mice. Thus, we concluded that MMR plays a significant role preventing the intestinal tumorigenesis induced by oxidative stress in mice.

Several lines of evidence suggest that oxidative stress could be generated in the intestines of animals under physiological conditions. For example, it was reported that the incidence of G:C to T:A transversions increases significantly in the intestines of older mice compared with younger mice (38). Because G:C to T:A transversions are mainly caused by 8-oxoG, a major oxidative DNA damage, these observations indicate that the mutations caused by oxidative DNA damage would tend to accumulate in the intestines during the course of aging. Consistent with this notion, defects in MUTYH, the human DNA glycosylase suppressing 8-oxoG-induced mutagenesis, lead to a susceptibility to colorectal cancers with excess G:C to T:A transversions in humans (39). Furthermore, *Mutyh*-deficient mice also show susceptibility to spontaneous and KBrO₃-induced intestinal adenoma/carcinoma (34). Therefore, based on these previous observations and our present results, it is likely that on a MMR-defective genetic background, oxidative stress generated in the intestine may enhance tumor development, thus leading to HNPCC in humans.

The mutation analyses of the tumor-related gene, *Cttnb1*, revealed that more than 30% of the tumors that developed in KBrO₃-treated *Msh2*-deficient mice had somatic mutations in the coding region for GSK3 β phosphorylation sites. All the mutations detected

were base substitutions; 20 G:C to A:T transitions (74.1%), three A:T to G:C transitions (11.1%), two G:C to T:A transversions and two G:C to C:G transversions (7.4%). These observations are consistent with the results obtained from mutation analyses of the *CTNNB1* gene in cancers from HNPCC patients; 12 reported base substitutions were as follows: TCT to TTT, CCT, or TGT at codon S45; ACC to GCC at codon T41; TCT to TGT at codon S37; GGA to GAA at codon G34; GAC to GGC or TAC at codon D32 (40). The G:C to A:T transition at codon G34 and G:C to C:G transversion at codon S37 were commonly observed in both human and mouse tumors. The difference observed between human and mouse mutation spectra may due to the different nucleotide sequence context in this locus of these two species. The similarity of the mutation types and spectra suggests that the KBrO₃-treatment of mice may mimic the oxidative stress in human to induce DNA damage in the intestine. We detected only two G:C to T:A transversions, thus suggesting that the DNA repair enzymes, including OGG1 and Mutyh, may suppress 8-oxoG-related mutagenesis to some extent in KBrO₃-treated *Msh2*-deficient mice. Besides the one G:C to T:A transversion at the codon for S33, three types of mutations other than the G:C to A:T transition were observed at only the codon for S37; three A:T to G:C transitions, two G:C to C:G transversions, and one G:C to T:A transversion. Because these types of mutations were suppressed by the overexpression of MTH1, which hydrolyzes oxidized purine nucleotide triphosphates, in *MSH2*-deficient human cells (28, 29), the nucleotide sequence context around the codon for S37 might be competent to enhance the incorporation of oxidatively-damaged purine nucleotide triphosphates by DNA polymerase.

MMR factors are well known to be involved in the induction of apoptosis caused by O⁶-methylguanine (O⁶-mG), a type of DNA damage produced by alkylating agents (19-21). O⁶-mG can pair with thymine during DNA replication, forming O⁶-mG:T mispairs. MutSα recognizes this mispair and forms a complex with MutLα and PCNA to induce apoptosis (20). The *Msh2*-deficiency also caused a failure to induce apoptosis effectively in response to oxidative DNA damage (26). Thus, in the present study, we analyzed the cell death of the crypts of small intestines from wild type and *Msh2*-deficient mice treated with KBrO₃ using a TUNEL assay. A larger number of TUNEL-positive cells were observed in the crypts from wild type mice compared with *Msh2*-deficient mice, suggesting that the crypt cells with MMR-deficiencies showed an increased chance of surviving protracted exposure to KBrO₃. The better survival of MMR-deficient cells with pre-mutagenic

lesions in the genome induced by oxidative stresses may contribute to the increased cancer risk characteristic of the hereditary non-polyposis colorectal cancer syndrome.

In conclusion, we herein demonstrated that oxidative stress enhanced the tumor formation in the small intestines of *Msh2*-deficient mice, thereby providing experimental evidence of the association between oxidative stress and hereditary non-polyposis colorectal cancer caused by MMR-deficiency in humans. We propose that MMR suppresses spontaneous tumorigenesis in the intestines of mammals by simultaneously preventing the occurrence of mutations and the removal of precancerous cells containing pre-mutagenic oxidative lesions in the genome.

Acknowledgements

We thank Dr. Brian Quinn for comments on the manuscript. We also appreciate the technical support from the Research Support Center, Graduate School of Medical Sciences, Kyushu University. This work was supported by grants from Japan Society for the Promotion of Science, and the Ministry of Health, Labor and Welfare of Japan.


Competing Interests

The authors have declared that no competing interest exists.

References

- Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. *Proc Natl Acad Sci USA*. 1993; 90: 7915-22.
- Gajewski E, Rao G, Nackerdien Z, Dizdaroglu M. Modification of DNA bases in mammalian chromatin by radiation-generated free radicals. *Biochemistry*. 1990; 29: 7876-82.
- Kasai H, Nishimura S. Hydroxylation of deoxyguanosine at the C-8 position by ascorbic acid and other reducing agents. *Nucleic Acids Res*. 1984; 12: 2137-45.
- Fraga CG, Shigenaga MK, Park JW, Degan P, Ames BN. Oxidative damage to DNA during aging: 8-hydroxy-2'-deoxyguanosine in rat organ DNA and urine. *Proc Natl Acad Sci USA*. 1990; 87: 4533-7.
- Shibutani S, Takeshita M, Grollman AP. Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. *Nature*. 1991; 349: 431-4.
- Smith KC. Spontaneous mutagenesis: experimental, genetic and other factors. *Mutat Res*. 1992; 277: 139-162.
- Radicella JP, Dherin C, Desmaze C, Fox MS, Boiteux S. Cloning and characterization of hOGG1, a human homolog of the OGG1 gene of *Saccharomyces cerevisiae*. *Proc Natl Acad Sci USA*. 1997; 94: 8010-5.
- Rosenquist TA, Zharkov DO, Grollman AP. Cloning and characterization of a mammalian 8-oxoguanine DNA glycosylase. *Proc Natl Acad Sci USA*. 1997; 94(14): 7429-34.
- Ohtsubo T, Nishioka K, Imaiso Y, et al. Identification of human Muty homolog (hMYH) as a repair enzyme for 2-hydroxyadenine in DNA and detection of multiple forms of hMYH located in nuclei and mitochondria. *Nucleic Acids Res*. 2000; 28:1355-64.
- Shinmura K, Yamaguchi S, Saitoh T, et al. Adenine excisional repair function of MYH protein on the adenine:8-hydroxyguanine base pair in double-stranded DNA. *Nucleic Acids Res*. 2000; 28: 4912-8.
- Slupski MM, Luther WM, Chiang JH, Yang H, Miller JH. Functional expression of hMYH, a human homolog of the *Escherichia coli* MutY protein. *J Bacteriol*. 1999; 181: 6210-3.
- Takao M, Zhang QM, Yonei S, Yasui A. Differential subcellular localization of human MutY homolog (hMYH) and the functional activity of adenine:8-oxoguanine DNA glycosylase. *Nucleic Acids Res*. 1999; 27: 3638-44.

13. Mo JY, Maki H, Sekiguchi M. Hydrolytic elimination of a mutagenic nucleotide, 8-oxodGTP, by human 18-kilodalton protein: sanitization of nucleotide pool. *Proc Natl Acad Sci USA*. 1992; 89: 11021-5.
14. Sakumi K, Furuichi M, Tsuzuki T, et al. Cloning and expression of cDNA for a human enzyme that hydrolyzes 8-oxo-dGTP, a mutagenic substrate for DNA synthesis. *J Biol Chem*. 1993; 268: 23524-30.
15. Fujikawa K, Kamiya H, Yakushiji H, et al. The oxidized forms of dATP are substrates for the human MutT homologue, the hMTH1 protein. *J Biol Chem*. 1999; 274: 18201-5.
16. Fujikawa K, Kamiya H, Yakushiji H, Nakabeppu Y, Kasai H. Human MTH1 protein hydrolyzes the oxidized ribonucleotide, 2-hydroxy-ATP. *Nucleic Acids Res*. 2001; 29: 449-54.
17. Bjelland S, Seeberg E. Mutagenicity, toxicity and repair of DNA base damage induced by oxidation. *Mutat Res*. 2003; 531: 37-80.
18. Iyer RR, Pluciennik A, Burdett V, Modrich PL. DNA mismatch repair: functions and mechanisms. *Chem. Rev*. 2006; 106: 302-23.
19. Stojic L, Brun R, Jiricny J. Mismatch repair and DNA damage signalling. *DNA Repair (Amst)*. 2004; 3: 1091-1101.
20. Hidaka M, Takagi Y, Takano TY, Sekiguchi M. PCNA-MutS α -mediated binding of MutL α to replicative DNA with mismatched bases to induce apoptosis in human cells. *Nucleic Acids Res*. 2005; 33: 5703-12.
21. Jiricny J. The multifaceted mismatch-repair system. *Nat Rev Mol Cell Biol*. 2006; 7: 335-46.
22. Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. *Cell*. 1993; 75: 1027-38.
23. Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a MutS homologue in hereditary nonpolyposis colorectal cancer. *Cell*. 1993; 75: 1215-25.
24. Bronner CE, Baker SM, Morrison PT, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. *Nature*. 1994; 368: 258-61.
25. Papadopoulos N, Nicolaides NC, Wei YF, et al. Mutation of a MutL homologue in hereditary colon cancer. *Science*. 1994; 263: 1625-9.
26. DeWeese TL, Shipman JM, Larrier NA, et al. Mouse embryonic stem cells carrying one or two defective Msh2 alleles respond abnormally to oxidative stress inflicted by low-level radiation. *Proc. Natl. Acad. Sci. USA*. 1998; 95: 11915-20.
27. Egashira A, Yamauchi K, Yoshiyama K, et al. Mutational specificity of mice defective in the MTH1 and/or the MSH2 genes. *DNA Repair (Amst)*. 2002; 1: 881-93.
28. Colussi C, Parlanti E, Degan P, et al. The mammalian mismatch repair pathway removes DNA 8-oxodGMP incorporated from the oxidized dNTP pool. *Current Biol*. 2002; 12: 912-8.
29. Russo MT, Blasi MF, Chiera F, et al. The oxidized deoxynucleoside triphosphate pool is a significant contributor to genetic instability in mismatch repair-deficient cells. *Mol Cell Biol*. 2004; 24: 465-74.
30. Kasai H, Nishimura S, Kurokawa Y, Hayashi Y. Oral administration of the renal carcinogen, potassium bromate, specifically produces 8-hydroxydeoxyguanosine in rat target organ DNA. *Carcinogenesis*. 1987; 8: 1959-1.
31. DeAngelo AB, George MH, Kilburn SR, Moore TM, Wolf DC. Carcinogenicity of potassium bromate administered in the drinking water to male B6C3F1 mice and F344/N rats. *Toxicol Pathol*. 1998; 26: 587-94.
32. Kurokawa Y, Maekawa A, Takahashi M, Hayashi Y. Toxicity and carcinogenicity of potassium bromate—a new renal carcinogen. *Environ Health Perspect*. 1990; 87: 309-35.
33. Kawanishi S, Murata M. Mechanism of DNA damage induced by bromate differs from general types of oxidative stress. *Toxicology*. 2006; 221: 172-8.
34. Sakamoto K, Tominaga Y, Yamauchi K, et al. MUTYH-null mice are susceptible to spontaneous and oxidative stress-induced intestinal tumorigenesis. *Cancer Res*. 2007; 67: 6599-604.
35. Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. *Gut*. 2000; 47: 251-5.
36. Polakis P. Wnt signaling and cancer. *Genes Dev*. 2000; 14: 1837-51.
37. Barker N, Ridgway RA, van Es JH, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. *Nature*. 2009; 457: 608-11.
38. Dolle ME, Snyder WK, Gossen JA, Lohman PH, Vijg J. Distinct spectra of somatic mutations accumulated with age in mouse heart and small intestine. *Proc Natl Acad Sci USA*. 2000; 97: 8403-8.
39. Al-Tassan N, Chmiel NH, Maynard J, et al. Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors. *Nat Genet*. 2002; 30: 227-32.
40. Miyaki M, Iijima T, Kimura J, et al. Frequent mutation of beta-catenin and APC genes in primary colorectal tumors from patients with hereditary nonpolyposis colorectal cancer. *Cancer Res*. 1999; 59: 4506-9.



OPEN

SUBJECT AREAS:

EVOLUTIONARY
BIOLOGY
MUTATIONReceived
8 January 2014Accepted
28 March 2014Published
15 April 2014Correspondence and
requests for materials
should be addressed to
K.S. (sakumi@bioreg.
kyushu-u.ac.jp)8-oxoguanine causes spontaneous *de novo* germline mutations in miceMizuki Ohno¹, Kunihiko Sakumi^{2,3}, Ryutaro Fukumura⁴, Masato Furuichi⁵, Yuki Iwasaki^{6,7},
Masaaki Hokama², Toshimichi Ikemura⁶, Teruhisa Tsuzuki¹, Yoichi Gondo⁴ & Yusaku Nakabeppu^{2,3}

¹Department of Medical Biophysics and Radiation Biology, Faculty of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan, ²Division of Neurofunctional Genomics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, Fukuoka 812-8582, Japan, ³Research Center for Nucleotide Pool, Kyushu University, Fukuoka 812-8582, Japan, ⁴Mutagenesis and Genomics Team, RIKEN BioResource Center, Tsukuba 305-0074, Japan, ⁵Radioisotope Center, Kyushu University, Fukuoka 812-8582, Japan, ⁶Department of Computer Bioscience, Nagahama Institute of Bio-Science and Technology, Nagahama 526-0829, Japan, ⁷Research Fellow of the Japan Society for the Promotion of Science.

Spontaneous germline mutations generate genetic diversity in populations of sexually reproductive organisms, and are thus regarded as a driving force of evolution. However, the cause and mechanism remain unclear. 8-oxoguanine (8-oxoG) is a candidate molecule that causes germline mutations, because it makes DNA more prone to mutation and is constantly generated by reactive oxygen species *in vivo*. We show here that endogenous 8-oxoG caused *de novo* spontaneous and heritable G to T mutations in mice, which occurred at different stages in the germ cell lineage and were distributed throughout the chromosomes. Using exome analyses covering 40.9 Mb of mouse transcribed regions, we found increased frequencies of G to T mutations at a rate of 2×10^{-7} mutations/base/generation in offspring of *Mth1/Ogg1/Mutyh* triple knockout (TOY-KO) mice, which accumulate 8-oxoG in the nuclear DNA of gonadal cells. The roles of MTH1, OGG1, and MUTYH are specific for the prevention of 8-oxoG-induced mutation, and 99% of the mutations observed in TOY-KO mice were G to T transversions caused by 8-oxoG; therefore, we concluded that 8-oxoG is a causative molecule for spontaneous and inheritable mutations of the germ lineage cells.

Evolution requires *de novo* germline mutations that are newly generated in germ lineage cells and inheritable to the offspring. It is evident that germline mutations occur, because sporadic and deleterious mutations that cannot be transmitted to offspring continuously appear in human populations^{1–4}. The human *de novo* germline mutation rate is estimated to be 1.20×10^{-8} /nucleotide/generation¹. However, the cause and mechanism of mutations in the germ cell lineage remain unclear. We hypothesized that the cause of these mutations would be endogenously and spontaneously generated and remain in the germ cell lineage. 8-oxoG is one of the candidate molecules for causing germline mutation, because it is endogenously generated by reactive oxygen species (ROS) derived from cellular respiration, constitutively exists in DNA⁵ and is known to cause G to T and A to C transversion mutations by the ability to pair with A as well as C during DNA replication^{6–8}.

Mammals possess three enzymes to avoid 8-oxoG-induced mutations. MTH1 (*mutT* homologue 1, NUDT1) degrades 8-oxodGTP in the nucleotide pool to prevent its incorporation into DNA⁹. OGG1 (8-oxoG DNA glycosylase) excises 8-oxoG from DNA^{10,11}, and MUTYH (*mutY* homologue, adenine DNA glycosylase) removes adenine misincorporated opposite 8-oxoG in DNA¹². We and other groups have reported that mice deficient in these enzymes are prone to developing cancer, indicating a mutator phenotype in somatic cells^{13–16}. MUTYH is also responsible for MUTYH-associated polyposis in humans¹⁷.

To evaluate the contribution of 8-oxoG to *de novo* germline mutation, we established the *Mth1/Ogg1/Mutyh* triple knockout (TOY-KO) mice, in which unrepaired endogenous 8-oxoG accumulates in the genome DNA. In this paper, using the TOY-KO mice, we showed that 8-oxoG causes G to T mutations in germ lineage cells (Supplementary Fig. S1 online).

Results

Spontaneous mutations increased in *Mth1*^{−/−}/*Ogg1*^{−/−}/*Mutyh*^{−/−} (TOY-KO) mice. To evaluate the contribution of 8-oxoG to *de novo* germline mutation, we established the TOY-KO mouse in the C57BL/6J background (>N16). TOY-KO mice are viable and fertile, although increased amounts of 8-oxoG accumulated in various tissues, including the gonads (Fig. 1a). Moreover, TOY-KO mice had a shorter lifespan (Fig. 1b) and developed various types of tumors (Fig. 1c). We maintained the TOY-KO mouse line originating from one pair




Figure 1 | Phenotype of TOY-KO mice. (a) Accumulation of 8-oxodG in TOY-KO mouse tissues. LC-MS/MS was used to determine the amount of 8-oxodG²⁹. Data are presented as the means \pm SD. Wilcoxon tests were used to analyze differences between TOY-KO (gray) and C57BL/6J;Jcl (open) mouse tissues (* $P < 0.05$; ** $P < 0.001$). (b) Survival of TOY-KO mice. The survival curve of TOY-KO mice ($n = 56$, indicated in red) was compared with that of *Mth1*^{+/-}/*Ogg1*^{+/-}/*Mutyh*^{+/-} (TOY-hetero) mice ($n = 14$, indicated in black). (c) A Harderian gland tumor (left) and a trichoepithelioma (right) observed in a TOY-KO mice (indicated by arrows). Hematoxylin and eosin staining of each tumor is shown. Scale bars, 200 μ m. (d) Numbers of newborn and weaned mice. Gray and red bars indicate the numbers of newborn and weaned mice in each generation of TOY-KO mice, respectively.

(G1) to the 8th generation (G8) by intragenerational mating (Supplementary Fig. S2 online). More than 35% of TOY-KO mice carried macroscopically distinguishable tumors (Supplementary Fig. S2 online). As the generations increased, it became difficult to obtain mice for breeding because of the decreased number of weaned mice (Fig. 1d). Several phenotypic variations were found among the progeny, such as hydrocephalus, belly white spot and anophthalmia (Supplementary Fig. S2 online). In cases of hydrocephalus and white spot, the traits were transmitted to the next generation in an autosomal dominant fashion with incomplete penetrance (Fig. 2, Supplementary Fig. S2 online). These features indicate that heritable mutations could arise in the TOY-KO mice.

To detect mutations that occur in the germ cell lineage and are transmitted across generations of TOY-KO mice, we performed whole exome sequencing analysis (Fig. 3a). We searched for different sequences between the C57BL/6J mouse reference genome (MGSCv37) and TOY-KO mice that belonged to the most advanced generation of each branch of the pedigree (TOY365F, TOY609F and TOY450F, shown in Fig. 3b). No sequencing reads corresponding to parts of the wild-type reference sequences of targeted *Mutyh*, *Mth1*, and *Ogg1* loci were obtained in chromosomes 4, 5, and 6, respectively (Supplementary Fig. S3 online), which confirmed that the TOY-KO mouse was indeed deficient for the three genes, and validated our exome analysis. By analyzing the exome covering 40.9 Mb of mouse transcribed sequences, which included 19,427

genes from 17 chromosomes, excluding chromosomes 4, 5, and 6 from the analysis to avoid ambiguity, we identified 262 base substitution mutations (Fig. 3c, Supplementary Table S1 online, Supplementary Data S1 online). No insertion/deletion mutations were detected in this analysis.

Identification of mutation origin mice. The 262 mutations detected in TOY365F, TOY609F and TOY450F had occurred in one of the mice in the 8-generations of the pedigree (Fig. 3b); therefore, we determined the mutation origin mouse that initially possessed the mutated allele in its tail DNA. We traced each mutation on the pedigree by determining the sequences of all mutated alleles in 35 TOY-KO mice shown in the pedigree (Fig. 3b), using MassArray or Sanger's sequencing, and identified the origin of each *de novo* mutation. The results of the sequencing are summarized in Supplementary Data S1 online with annotations. Among them, we considered that 247 mutations found in G2–G8 mice had spontaneously occurred in the germ cell lineage of TOY-KO mice, because these mutated alleles were derived from gametes of their parent mice (G1–G7) or were generated during early development of the mice (G2–G8). The spectrum of germline mutation observed in TOY-KO mice indicated a distinct feature: 99% (244/247) of the mutations were G to T transversions (Table 1). G to T mutations had specifically increased in TOY-KO mice lacking the ability to avoid 8-oxoG-induced mutations; therefore, we concluded that 8-oxoG is a causative